Vaxcyte, Inc.
PCVX
株式のランク
#2112
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
株価
$63.40
最終同期: 2026-10-16
時価総額
$9.72B
変化（1日）
-2.87%
変化（1年）
49.56%
国
US
取引 Vaxcyte, Inc. (PCVX)
カテゴリー
Healthcare
Vaxcyte, Inc.（PCVX）のEPS
June 2026 時点のEPS TTM: $-7.64
Vaxcyte, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-7.64です。2023年末には、EPSは$-4.14で、2022年のEPS$-3.44と増加でした。
Vaxcyte, Inc.のEPS履歴（2017から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-7.64 | 101.05% |
| 2024 | $-3.80 | -8.21% |
| 2023 | $-4.14 | 20.35% |
| 2022 | $-3.44 | 78.24% |
| 2021 | $-1.93 | -35.02% |
| 2020 | $-2.97 | -78.94% |
| 2019 | $-14.10 | 73.65% |
| 2018 | $-8.12 | 67.77% |
| 2017 | $-4.84 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -326.70% |
US
|
|
| $-7.98 | 4.45% |
US
|
|
| $-5.29 | -30.76% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -463.09% |
NL
|
